| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Willian Lazarini-Lopes, Raquel A Do Val-da Silva, Rui M P da Silva-Júnior, Gleice K Silva-Cardoso, Christie R A Leite-Panissi, João P Leite, Norberto Garcia-Cairasc. Chronic cannabidiol (CBD) administration induces anticonvulsant and antiepileptogenic effects in a genetic model of epilepsy. Epilepsy & behavior : E&B. vol 119. 2021-06-29. PMID:33887676. |
cannabidiol (cbd) is a marijuana compound implicated in epilepsy treatment in animal models and pharmacoresistant patients. |
2021-06-29 |
2023-08-13 |
rat |
| Taylor E Savage, Jo Sourbron, Patricia L Bruno, Lauren A Skirvin, Emma S Wolper, Christina J Anagnos, Elizabeth A Thiel. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. Epilepsy research. vol 160. 2021-06-25. PMID:31923763. |
efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. |
2021-06-25 |
2023-08-13 |
human |
| Taylor E Savage, Jo Sourbron, Patricia L Bruno, Lauren A Skirvin, Emma S Wolper, Christina J Anagnos, Elizabeth A Thiel. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. Epilepsy research. vol 160. 2021-06-25. PMID:31923763. |
to evaluate the efficacy of open-label, highly purified cannabidiol (cbd, epidiolex®) in treating refractory epilepsy relative to the concomitant use of clobazam (clb) as well as the clinical implications of changes in clb and norclobazam (nclb) levels. |
2021-06-25 |
2023-08-13 |
human |
| Ece Unal, Brigitte Anderson, Andrew Helber, John H Mark. Cannabinoids: A Guide for Use in the World of Gastrointestinal Disease. Journal of clinical gastroenterology. vol 54. issue 9. 2021-06-24. PMID:31789770. |
medical cannabis has since been offered as a treatment for a myriad of conditions and malignancies, including cancer, human immunodeficiency virus/acquired immunodeficiency syndrome, multiple sclerosis, chronic pain, nausea, posttraumatic stress disorder, amyotrophic lateral sclerosis, cachexia, glaucoma, and epilepsy. |
2021-06-24 |
2023-08-13 |
human |
| Christopher J Perry, Paul Finch, Annette Müller-Taubenberger, Kit-Yi Leung, Eleanor C Warren, Joseph Damstra-Oddy, Devdutt Sharma, Pabitra H Patra, Sarah Glyn, Joanna Boberska, Balint Stewart, Amy Baldwin, Fabiana Piscitelli, Robert J Harvey, Adrian Harwood, Christopher Thompson, Sandrine P Claus, Nicholas D E Greene, Alister J McNeish, Claire M Williams, Benjamin J Whalley, Robin S B William. A new mechanism for cannabidiol in regulating the one-carbon cycle and methionine levels in Dictyostelium and in mammalian epilepsy models. British journal of pharmacology. vol 177. issue 4. 2021-06-21. PMID:31693171. |
a new mechanism for cannabidiol in regulating the one-carbon cycle and methionine levels in dictyostelium and in mammalian epilepsy models. |
2021-06-21 |
2023-08-13 |
Not clear |
| Claire M Williams, Gary J Stephen. Development of cannabidiol as a treatment for severe childhood epilepsies. British journal of pharmacology. vol 177. issue 24. 2021-06-21. PMID:32986848. |
development of cannabidiol as a treatment for severe childhood epilepsies. |
2021-06-21 |
2023-08-13 |
human |
| Lyndsey L Anderson, Adam Ametovski, Jia Lin Luo, Declan Everett-Morgan, Iain S McGregor, Samuel D Banister, Jonathon C Arnol. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS chemical neuroscience. vol 12. issue 2. 2021-06-18. PMID:33395525. |
cannabichromene (cbc) is a phytocannabinoid frequently detected in artisanal cannabis oils used in the community by childhood epilepsy patients. |
2021-06-18 |
2023-08-13 |
mouse |
| Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amode. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. International journal of molecular sciences. vol 22. issue 9. 2021-06-17. PMID:34062987. |
cannabidiol (cbd), the major nonpsychoactive cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. |
2021-06-17 |
2023-08-13 |
Not clear |
| Andrew J Roebuck, Quentin Greba, Anna-Maria Smolyakova, Mariam Alaverdashvili, Wendie N Marks, Sumanta Garai, Samantha L Baglot, Gavin Petrie, Stuart M Cain, Terrance P Snutch, Ganesh A Thakur, Matthew N Hill, John G Howland, Robert B Laprairi. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology. vol 190. 2021-06-09. PMID:33845076. |
certain cannabinoids, such as cannabidiol (cbd), have shown promise in the treatment of pediatric epilepsies. |
2021-06-09 |
2023-08-13 |
rat |
| Vaishali Satpute Janve, Lyndsey L Anderson, Dilara Bahceci, Nicole A Hawkins, Jennifer A Kearney, Jonathon C Arnol. The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the Frontiers in pharmacology. vol 12. 2021-06-05. PMID:34079465. |
the heat sensing trpv1 receptor is not a viable anticonvulsant drug target in the cannabidiol has been approved for the treatment of drug-resistant childhood epilepsies including dravet syndrome (ds). |
2021-06-05 |
2023-08-13 |
Not clear |
| Shah Khalid, Faisal A Almalki, Taibi Ben Hadda, Ammar Bader, Tareq Abu-Izneid, Malika Berredjem, Eman R Elsharkawy, Ali M Alqahtan. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19? Current pharmaceutical design. vol 27. issue 13. 2021-06-04. PMID:33267756. |
however, the approval of some cannabinoids by the fda (along with other recognized national medical health systems) has opened the horizon for the use of these natural drugs in medicines such as epidiolex® (cannabidiol, used for the treatment of severe forms of epilepsy) and sativex®(Δ |
2021-06-04 |
2023-08-13 |
Not clear |
| J Helen Cross, Hannah Coc. A perspective on cannabinoids for treating epilepsy: Do they really change the landscape? Neuropharmacology. vol 170. 2021-06-03. PMID:31770546. |
with the licensing of cannabidiol for drug resistant seizures in dravet and lennox gastaut syndromes in the united states in 2018, interest in the potential for cannabis-based-medicinal products to meet currently unmet needs for people with epilepsy continues to grow. |
2021-06-03 |
2023-08-13 |
Not clear |
| Rhys Richard Mould, Stanley W Botchway, James R C Parkinson, Elizabeth Louise Thomas, Geoffrey W Guy, Jimmy D Bell, Alistair V W Nun. Cannabidiol Modulates Mitochondrial Redox and Dynamics in MCF7 Cancer Cells: A Study Using Fluorescence Lifetime Imaging Microscopy of NAD(P)H. Frontiers in molecular biosciences. vol 8. 2021-05-30. PMID:34046425. |
cannabidiol modulates mitochondrial redox and dynamics in mcf7 cancer cells: a study using fluorescence lifetime imaging microscopy of nad(p)h. the cannabinoid, cannabidiol (cbd), is part of the plant's natural defense system that when given to animals has many useful medicinal properties, including activity against cancer cells, modulation of the immune system, and efficacy in epilepsy. |
2021-05-30 |
2023-08-13 |
Not clear |
| Lyndsey L Anderson, Ivan K Low, Iain S McGregor, Jonathon C Arnol. Interactions between cannabidiol and Δ British journal of pharmacology. vol 177. issue 18. 2021-05-27. PMID:32608111. |
interactions between cannabidiol and Δ extracts from the cannabis plant can dramatically improve the health of children suffering from refractory epilepsies such as dravet syndrome. |
2021-05-27 |
2023-08-13 |
Not clear |
| Alexander Doyle, Jay Harve. Cannabis and Epilepsy. Journal of dual diagnosis. vol 16. issue 1. 2021-05-21. PMID:31385740. |
cannabis and epilepsy. |
2021-05-21 |
2023-08-13 |
Not clear |
| Francesca Marchese, Maria Stella Vari, Ganna Balagura, Antonella Riva, Vincenzo Salpietro, Alberto Verrotti, Rita Citraro, Simona Lattanzi, Carlo Minetti, Emilio Russo, Pasquale Strian. An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy. Cannabis and cannabinoid research. 2021-05-17. PMID:33998856. |
an open retrospective study of a standardized cannabidiol based-oil in treatment-resistant epilepsy. |
2021-05-17 |
2023-08-13 |
Not clear |
| Marguerite Le Marois, Véronique Ballet, Camille Sanson, Magali-Anne Maizières, Thierry Carriot, Céline Chantoiseau, Michel Partiseti, Georg Andrees Bohm. Cannabidiol inhibits multiple cardiac ion channels and shortens ventricular action potential duration in vitro. European journal of pharmacology. vol 886. 2021-05-14. PMID:32910945. |
cannabidiol (cbd) is a non-psychoactive component of cannabis which has recently received regulatory consideration for the treatment of intractable forms of epilepsy such as the dravet and the lennox-gastaut syndromes. |
2021-05-14 |
2023-08-13 |
human |
| Katherine S Ong, John B Carlin, Michael Fahey, Jeremy L Freeman, Ingrid E Scheffer, Lynn Gillam, Monique Anderson, Md Hamidul Huque, Donna Legge, Nicole Dirnbauer, Brian Lilley, Simon Slota-Kan, Noel Cranswic. Protocol for a single patient therapy plan: A randomised, double-blind, placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsy. Journal of paediatrics and child health. vol 56. issue 12. 2021-05-14. PMID:32965057. |
protocol for a single patient therapy plan: a randomised, double-blind, placebo-controlled n-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsy. |
2021-05-14 |
2023-08-13 |
Not clear |
| Katherine S Ong, John B Carlin, Michael Fahey, Jeremy L Freeman, Ingrid E Scheffer, Lynn Gillam, Monique Anderson, Md Hamidul Huque, Donna Legge, Nicole Dirnbauer, Brian Lilley, Simon Slota-Kan, Noel Cranswic. Protocol for a single patient therapy plan: A randomised, double-blind, placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsy. Journal of paediatrics and child health. vol 56. issue 12. 2021-05-14. PMID:32965057. |
the sptp has been designed to assess the efficacy at an individual level of a commercially available cannabinoid product, cannabidiol, in reducing seizure frequency in paediatric patients with intractable epilepsy. |
2021-05-14 |
2023-08-13 |
Not clear |
| Aditya Krishnan, Juliana Chizo Agwu, Chetana Kallappa, Rajesh Pande. Development of central precocious puberty following cannabinoid use for paediatric epilepsy: causal or coincidence? BMJ case reports. vol 14. issue 4. 2021-05-14. PMID:33858879. |
research suggests a role for cannabidiol oil in managing certain forms of paediatric onset epilepsy. |
2021-05-14 |
2023-08-13 |
monkey |